COMP <GO>
SOLV vs GMED // ENTERPRISE SCALE & MARKET CAP
Solventum Corporation (NYSE) VS. Globus Medical Inc. (NYSE) • 15-METRIC TALLY: SOLV 6
— GMED 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: SOLV
LAST: $83.56 (+2.09%) • MKT CAP: $14.22B
market-cap
$14.22B
LAST: $82.91 (+2.03%) • MKT CAP: $11.13B
market-cap
$11.13B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SOLV VS. GMED)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SOLV | GMED | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 67.40% | -13.90 | GMED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.70% | 8.70% | +10.00 | SOLV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.3x | 17.6x | -10.30 | SOLV | /valuation <GO> |
| Free Cash Flow Yield | -0.07% | 5.29% | -5.36 | GMED | /fcf-yield <GO> |
| Operating Margin | 26.20% | 16.30% | +9.90 | SOLV | /operating-margins <GO> |
| Net Profit Margin | 18.70% | 18.30% | +0.40 | SOLV | /net-margins <GO> |
| Revenue Growth (YoY) | 0.90% | 16.70% | -15.80 | GMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 10.74 | -8.49 | GMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | GMED | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.4 | 59.8 | -16.40 | GMED | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.07 | -0.01 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 17.4x | -8.90 | SOLV | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $14.22B | $11.13B | $3.09B | SOLV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SOLV REV | GMED REV | SOLV GROSS % | GMED GROSS % | SOLV FCF | GMED FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.32B | $2.94B | 53.5% | 67.4% | -$10.0M | $588.8M |
| FY 2024 | $8.25B | $2.52B | 55.6% | 58.9% | $805.0M | $405.2M |
| FY 2023 | $8.20B | $1.57B | — | — | $1.55B | $172.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SOLV // BETA 1.06
GMED // BETA 1.07